Introduction
The development and persistence of antimicrobial resistance (AMR) has become an international problem for patients and physicians alike. Well-documented evidence exists detailing the relationship between antimicrobial use and the development of resistance. 1 Consequently, the use of antimicrobials must be reduced in order to safeguard the efficacy of antimicrobial agents for future generations. Mathematical models support the reduction of community-level antimicrobial use to reduce AMR. These models show that in a community with a constant rate of antimicrobial consumption and with the presence of susceptible and resistant strains, the prevalence of resistance will increase in a sigmoidal fashion. 1 Further evidence for the reduction of group-level antimicrobial use to reduce AMR is the successful reduction of resistance following stewardship programmes and formulary changes at the hospital level. 2, 3 In order to reduce antimicrobial use, the issue of inappropriate prescribing must be addressed, especially in the case of viral respiratory infections. Although these conditions are generally not overcome by antimicrobial therapy, rates of prescribing are high. 4 -6 In 1999, 51% of the antibiotics prescribed to preschool children in Saskatchewan were for viral respiratory infections, and were thus inappropriate. 7 Moreover, inappropriate prescribing for respiratory viral infections was found to occur at various rates in Québec depending on diagnosis, from 22% for laryngitis and up to 43% for influenza cases. 8 Although Canada has a universal healthcare system for all citizens that covers fees for physician visits, prescription drugs are not covered. Public drug coverage is available for specific socioeconomic groups, and private plans are often accessed through employers. Therefore, use of prescription drugs may be different among socioeconomic groups. Due to the impact of antimicrobial use on AMR, studies have been undertaken to determine significant predictors for antimicrobial use, including socioeconomic factors. For example, a significant association between family income and antimicrobial prescribing was found in a study of children in Manitoba. 9 This study concluded that the likelihood of receiving an inappropriate antimicrobial prescription was reduced with each successive increase of $10000 in median family income. These smaller-scale studies of particular demographic groups provide useful information on predictors that may also be significant at the community or provincial level, where policies and guidelines may be introduced.
A documented relationship exists between macrolide consumption and resistance in Streptococcus pneumoniae, the most frequently identified cause of community-acquired respiratory infections. 10, 11 Thus, knowledge of predictors for macrolide use is of great importance. Therefore, the objective of this study was to determine significant associations among the rate of influenza and various socioeconomic measures on the consumption of individual macrolide antimicrobials in Canada. Examining each drug separately allows for comparisons between patterns of use for broad-spectrum and narrow-spectrum drugs, and among drugs priced differently.
Materials and methods

Data sources
The Intercontinental Medical Statistics (IMS) Canada CompuScript TM data set was obtained from the Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS). Defined daily dose (DDD) calculations were performed by CIPARS according to the Anatomical Therapeutic Chemical Classification system from the World Health Organization (WHO). 12, 13 A DDD is defined by the WHO as 'the assumed average maintenance dose per day for a drug used for its main indication in adults'. 12 Data were supplied monthly for each individual province except Prince Edward Island (PEI) and Newfoundland (NFLD), for which data were combined. The study period was from January 2000 to December 2006, which resulted in a total of 756 data points for examination. Data describing macrolide use were extracted from the CompuScript TM data set. The macrolide agents spiramycin and telithromycin were excluded from analysis as they were not prescribed in all provinces throughout the study period. This resulted in three macrolides for study: azithromycin, clarithromycin and erythromycin.
Socioeconomic data were collected from census counts, extrapolations and estimates as compiled by Statistics Canada. Monthly estimates were available for percent unemployment and education (as described by the number of individuals with a bachelor's degree), quarterly estimates were available for population totals, and yearly estimates were available for median family income, number of individuals considered low income and number of healthcare workers, which was a count of all individuals in human health occupations including health professionals, registered nurses, technicians and assistants. 14 -18 Influenza data were obtained from FluWatch, the national surveillance system for influenza facilitated by the Public Health Agency of Canada. FluWatch provides passive surveillance data for influenza and influenza-like illnesses from samples sent by physicians to sentinel laboratories. For this study, counts of laboratory-confirmed cases of influenza were obtained from 2000 to 2006. Finally, to account for seasonal variation within years, a quarter variable was produced where a quarter was defined as follows: quarter one included January, February and March; quarter two included April, May and June; quarter three included July, August and September; and quarter four included October, November and December.
Statistical analyses
All statistical analyses were performed using STATA Intercooled 9.1. To meet the linear model assumptions of normality and homoscedasticity, base 10 logarithmic (log 10 ) transformations were performed on all DDD per capita data. 19 Collinearity of predictor variables was tested using Pearson correlation analysis, and pairs of variables with absolute Pearson correlation values .0.8 were considered to be of concern for collinearity. 19 If a pair of predictor variables was significantly correlated, the predictor that was considered to be more informative was retained. Linearity of continuous predictors with the log 10 DDDs per capita data was assessed visually using lowess smoothers. 19 To address non-linearity, quadratic terms were assessed using a P value cut-off of 0.05. If a quadratic term was significant and adequately described the relationship between the predictor and the outcome, then it was included in the model. If the quadratic term was not significant, or did not adequately describe the non-linear relationship between the predictor and the outcome, then the predictor variable was treated as a categorical variable. For example, the year variable was modelled using dummy variables for each year since changes in DDDs over time were not linear and they could not be adequately described with the addition of a quadratic term to the model.
A manual model-building approach was employed. Quarter, year and province were forced into all models to control for potential confounding effects and clustering by space and time. A P value of 0.05 was used to determine if a predictor was acceptable for inclusion in the final models. Confounding was assessed throughout model development, and was defined as a 20% change in any statistically significant coefficient in the model with the addition or removal of another variable. 19 If a variable was determined to be a confounder, it was included in the final multivariable model, regardless of its statistical significance. Interaction terms were generated and tested between influenza and the unemployment, education, low income and median family income variables. Interaction terms were assessed for statistical significance within each main effects model. Variables not included in the model were reintroduced at the end of the model-building process to assess potential confounding.
Outlier and residual analyses
Outliers and influential points were assessed for all models, and normality and homogeneity of variance were also assessed. Data for outlying observations or observations showing a large degree of influence on the model coefficients were examined for potential recording errors.
Back transformation of data
Estimated coefficients were back transformed from the log 10 scale by exponentiating 10 to the power of each coefficient (10 b ). This practice results in a measure of the proportion change from the referent category (e.g. a value of 0.45 would indicate that the measure is 45% of the referent measure).
Results and discussion
Descriptive statistics for all socioeconomic and influenza variables are included in Table 1 .
Patterns of macrolide use over time
The CIPARS 2006 report suggests that consumption of macrolides in Canada is not constant throughout the year, and results here support these findings. 13 From model results,
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JAC consumption of all macrolides was highest during quarter one (January-March); however, use of azithromycin and clarithromycin in the first quarter was not significantly different from that in the fourth quarter (October-December) ( Table 2 ). These results indicate that peaks in macrolide use occur during the autumn and winter seasons, which support similar findings by the European Surveillance of Antimicrobial Consumption (ESAC) project. 20 This suggests that ecological mathematical models describing the effect of antimicrobial use on AMR that assume a constant selection pressure do not capture the entirety of variation of macrolide use.
Azithromycin use increased from 2000 to 2003, and levelled off in subsequent years (Table 2) . Clarithromycin use showed an overall increase in use over the study period (Table 2 ) and, contrastingly, the erythromycin model showed a trend of decreasing consumption over this same time frame (Table 2) . These results suggest that despite overall reductions in antimicrobial consumption in the 1990s, 6 ,21,22 these reductions were not consistent across all macrolides throughout the first half of the 2000s. The broad-spectrum agents azithromycin and clarithromycin increased in use, while use of the narrower-spectrum erythromycin was reduced. This complements research in the USA, where an increase in broad-spectrum and a decrease in narrower-spectrum macrolide use by children was seen from 1995 to 2000. 23 The decline in erythromycin and increase in azithromycin and clarithromycin use may be attributed to the preferred treatment regimen of azithromycin and clarithromycin as compared with erythromycin, and the reduction in gastrointestinal side effects. 23 
Provincial variations in macrolide use
Significant differences in macrolide use were apparent among provinces for all three macrolides investigated ( Table 2) . Differences in provincial use patterns are probably attributable to the wide variety of provincial formularies dictating financial drug coverage, and therefore access to antimicrobials across the country. 24 As first-line treatment with the once and twice a day macrolide agents (azithromycin and clarithromycin, respectively) was shown to be associated with the development of AMR, 25, 26 further research into the policies and procedures used in the province with low broad-spectrum use (British Columbia) may provide insight on how the per capita use of broadspectrum macrolides may be reduced nationwide. It is apparent from model results that, in British Columbia, erythromycin may be used preferentially over azithromycin and clarithromycin, which may be effective in decreasing AMR development due to decreased broad-spectrum use.
Healthcare workers
The curvilinear relationship between the health workers variable and clarithromycin use showed that consumption initially declined with increasing number of healthcare workers and then increased again as the number of healthcare workers reached its highest recorded level (Table 2 and Figure 1a) . These results may reflect accessibility to physicians and specialists in populations with varying numbers of healthcare providers, and differential treatment behaviours between physicians and specialists. At low levels of this variable, it is likely that physicians are required to see a large number of patients per day, and it has been shown that as patient volume increases prescribing occurs at a higher rate. 27 Therefore, as the number of health workers per capita in a population increases, macrolide prescribing may be expected to decline. This was seen up to median values of the variable; however, a positive relationship with macrolide prescribing was seen at greater values of this variable. This positive relationship may be attributed to accessibility to specialists; it may be expected that the proportion of specialists would increase as the number of health workers per capita increased, and it has been shown that specialists such as paediatricians prescribe second-line antimicrobials (such as clarithromycin) at a higher rate than general physicians. 9 
Socioeconomic factors
Similar to the relationship detailed for the health workers variable, the results pertaining to median family income may be attributed to healthcare access or unequal treatment of individuals among socioeconomic groups. In the clarithromycin model, median family income was significant with its quadratic term, producing a curvilinear relationship where initially clarithromycin use increased as median family income increased, but declined as median family income reached its median and maximal values ( Table 2 and Figure 1b ). The azithromycin model also included median family income with its quadratic term, producing a positive relationship that levelled off at higher income levels ( Table 2 and Figure 1c) , and erythromycin use was positively associated with median family income ( Table 2) . Although access to healthcare is expected to be equal across income Glass et al.
groups in Canada, it has been found that visits to general practitioners and specialists are more likely in higher income classes. 28 Thus, as treatment is accessed more frequently by families with higher incomes, use is expected to be higher in these groups, as seen in the azithromycin and erythromycin models. In contrast, the results for clarithromycin showed the opposite relationship to median family income, and this may be attributable to another factor influencing access to care: drug costs. During the study period, clarithromycin had the highest per-treatment cost. 29 As co-payment (percentage of Risk factors for macrolide use in Canada 151 JAC the overall cost that is paid out of pocket by the consumer) may increase with median family income for some drug plans, azithromycin may be chosen over the more expensive clarithromycin, as treatment efficacy and incidence of side effects have been shown to be similar between the two drugs. 30, 31 These findings are also highlighted by the low income variable, where similar relationships were seen with decreased clarithromycin and increased azithromycin and erythromycin use in the most advantaged populations (Table 2 and Figure 1d and e) . Furthermore, all models developed displayed a similar relationship between unemployment and use (Figure 1f) , where a negative relationship was seen between minimum and median values of unemployment, followed by a positive relationship as percent unemployment increased. Thus, physicians may choose the antimicrobial treatment based upon expectations of patient's drug coverage or ability to pay.
Knowledge of appropriate antimicrobial use
Within the model describing erythromycin use, education was significant with its quadratic term, and graphs of the predicted values showed a decline that becomes steeper as percent education increased towards its maximum recorded values (Table 2 and Figure 2a) . The negative association between education and macrolide use is expected; it is believed that higher population education levels reflect better knowledge concerning appropriate antibiotic use, thus it may be expected that populations with higher education levels are less likely to request unwarranted macrolide prescriptions. These results are consistent with previous research conducted in Denmark and Spain, where it was found that increasing education levels were negatively associated with macrolide consumption. 10, 32 Moreover, low educational levels in Spain have also been associated with Glass et al.
increased AMR with regard to erythromycin. 10 Thus, targeted education programmes may be warranted to reduce macrolide consumption and resistance in populations with lower than average educational levels. Contrastingly, education was significant with its quadratic term in the model describing azithromycin, creating a curvilinear relationship that initially increased and levelled off as the levels of education in the population approached their maximum recorded values (Figure 2b) . The contradictory results for azithromycin may reflect increased knowledge surrounding the simplified treatment protocols for azithromycin in a highly educated population, whether through patient research and request or differing physician communication with patients of varying education levels. Furthermore, due to the high rates of prescribing for children, a single dose per day regimen such as that for azithromycin may be more convenient for those parents of patients that work outside the home, which may be more common in populations with high education levels. 
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Effect of influenza on macrolide use
The rate of influenza was significantly associated with use in all models with its quadratic term, producing a positive relationship that levelled off at high influenza rates (Figure 2c ). These associations may reflect the inappropriate prescribing and consumption of macrolide antimicrobials to treat viral infections and/or prescribing for secondary bacterial infections.
Interactions between the rate of influenza and socioeconomic variables were significant in the models describing clarithromycin and erythromycin use, and provide insight on populations that may be suitable for targeting with programmes for reducing macrolide use. The clarithromycin model included the following significant interaction terms: the rate of influenza with percent unemployment; and the rate of influenza with percentage of the population considered to be low income. Graphs produced with the predicted values indicated that the demand for clarithromycin was highest in populations with the maximum values of percent unemployment as the rate of influenza increased (Table 2 and Figure 3a) . Similarly, the greatest increase in demand for clarithromycin was seen in populations with high percentages of low income individuals as the rate of influenza increased (Figure 3b ). Influenza interacted with percent education in the model describing erythromycin use, showing that populations with minimum values of percent education had the highest demand for erythromycin as the influenza rate increased (Figure 3c ). These significant interactions indicate that populations with low percentages of individuals with bachelor's degrees, those with high rates of unemployment and those with high percentages of low income individuals may be at the highest risk for inappropriate macrolide use as the rate of influenza increases. Thus, these populations may benefit from targeted interventions for macrolide stewardship, especially educational material surrounding the virus versus bacteria problem or the importance of influenza vaccination if these results reflect secondary infections. Modelling results at the provincial level produced results that were consistent with those obtained from individual-level studies. Our results support further research surrounding antimicrobial use in various socioeconomic populations in Canada to determine the impact of physician behaviours or patient factors on antimicrobial use, and to determine whether the influenza variable described here reflects inappropriate prescribing or the treatment of secondary bacterial infections. However, as data were collected and analysed at the provincial level in this study, care should be taken to avoid extrapolating these results to the level of the individual to avoid ecological bias. Further large-scale studies incorporating individual-and community-level variables are recommended to fully understand the influence of disease, socioeconomic factors and formulary policies on the macrolide drug consumption patterns of individual Canadians and their communities.
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